Journal of Hepatology
Volume 51, Issue 1 , Pages 21-28 , July 2009

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

  • Avidan U. Neumann

      Affiliations

    • Bar-Ilan University, Goodman Faculty of Life Sciences, Bldg. 212, Rm. 210, 52900 Ramat-Gan, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 3 5317970; fax: +972 3 6356353.
    • ,
  • Stephen Pianko

      Affiliations

    • Monash University Medical School, Victoria, Australia
    • ,
  • Stefan Zeuzem

      Affiliations

    • J.W. Goethe-University Hospital, Frankfurt, Germany
    • ,
  • Eric M. Yoshida

      Affiliations

    • University of British Columbia, Vancouver, Canada
    • ,
  • Yves Benhamou

      Affiliations

    • Hôpital Pitié-Salpêtrière, Paris, France
    • ,
  • Moshe Mishan

      Affiliations

    • Bar-Ilan University, Goodman Faculty of Life Sciences, Bldg. 212, Rm. 210, 52900 Ramat-Gan, Israel
    • ,
  • John G. McHutchison

      Affiliations

    • Division of Gastroenterology, Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Erik Pulkstenis

      Affiliations

    • Human Genome Sciences, Inc., Rockville, MD, USA
    • ,
  • G. Mani Subramanian

      Affiliations

    • Human Genome Sciences, Inc., Rockville, MD, USA

Received 14 November 2008 ,Revised 22 December 2008 ,Accepted 12 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ The authors (except M. Misham) who have taken part in this study have declared a relationship with the manufacturers of the drugs involved. G. Mani Subramanian and E. Pulkstenis are employees of Human Genome Sciences Inc., Rockville, Maryland, USA. J.G. McHutchison has received research grants from HGS, for conduct of this and other clinical trials related to this drug. All funding received from HGS Inc. went towards the cost of the clinical trial. A. Neumann is a consultant for and has received research grants from Human Genome Sciences Inc., Rockville, Maryland, USA. SP, SZ, EMY and YB are all investigators on trails related to this drug. M. Misham has nothing to disclose. ClinicalTrials.gov identifier NCT00115908.

PII: S0168-8278(09)00089-0

doi: 10.1016/j.jhep.2009.01.017

Journal of Hepatology
Volume 51, Issue 1 , Pages 21-28 , July 2009

Article Tools

* Image Usage & Resolution